Oracle
ORCL
Alibaba
BABA
NVIDIA
NVDA
Advanced Micro Devices
AMD
Cisco
CSCO
US Stock MarketDetailed Quotes
CANF Can-Fite BioPharma
- 1.5600
- +0.0300+1.96%
Trading Feb 18 11:31 ET
9.51MMarket Cap-0.60P/E (TTM)
1.6000High1.5400Low102.15KVolume1.5650Open1.5300Pre Close160.02KTurnover1.89%Turnover RatioLossP/E (Static)6.10MShares4.690052wk High3.83P/B8.45MFloat Cap1.290052wk Low--Dividend TTM5.42MShs Float1419.0000Historical High--Div YieldTTM3.92%Amplitude1.2900Historical Low1.5660Avg Price1Lot Size
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Can-Fite BioPharma Stock Forum
The clinical results from Can-Fite's Namodenoson represent a potentially significant breakthrough in the treatment of decompensated liver cirrhosis. The observed improvements in multiple key disease markers are particularly noteworthy:
Resolution of moderate ascites and elimination of diuretic dependency, indicating improved liver function and portal hypertension management
Cessation of gastrointestinal bleeding episodes, sugg...
Liver Cirrhosis Breakthrough: Patient's Remarkable Recovery Sparks Hope for 10.6M Sufferers
Can-Fite BioPharma's Namodenoson Shows Potential To Stabilize Advanced Liver Cirrhosis, Offering New Hope Amid Limited Treatment Options
Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson
Tuesday, 18th February at 7:00 am
Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 2030
Ramat Gan, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseas...
When and where will Can-Fite BioPharma (CANF) present at the BIO CEO Conference 2025?
Can-Fite BioPharma will present on February 10, 2025, at 3:45 pm EST at the New York Marriott Marquis in New York City.
What clinical trials is CANF currently conducting with Namodenoson?
Namodenoson is currently in a pivotal Phase III trial for advanced liver cancer and a Phas...
heading up from here
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you d...
No comment yet